Akebia Therapeutics, Inc. (AKBA)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-01

Key Insights

Akebia Therapeutics announced the resignation of a Class I director, Steven C. Gilman, and the appointment of a new Class I director, Philip J. Vickers, effective April 1, 2026.
The new director, Philip J. Vickers, has been appointed to the Compensation Committee and the Research & Development Committee of the Board.
Vickers will receive standard non-employee director compensation, including annual cash retainers and equity grants in the form of stock options and restricted stock units.

Current Report Filed: 2026-01-30

Key Insights

Akebia Therapeutics signed a new 84-month lease for 43,474 square feet of office and laboratory space in Waltham, Massachusetts, relocating its corporate headquarters from Cambridge.
The company's CEO, John P. Butler, signed an amended executive severance agreement that provides enhanced severance benefits, including 12-24 months of base salary continuation and bonus payments, in the event of termination without cause or resignation for good reason.
The new lease and executive severance agreement represent material changes to Akebia's operations and leadership, which could have a significant impact on the company's financial and strategic positioning.

Current Report Filed: 2026-01-12

Key Insights

Akebia Therapeutics provided a positive business update, highlighting the commercial performance of its lead drug Vafseo and upcoming milestones for its rare kidney disease pipeline.
The company reported expected Q4 2025 net product revenue for Vafseo, indicating continued commercial traction for this key asset.
Akebia plans to present an updated corporate presentation at the upcoming J.P. Morgan Healthcare Conference, providing investors with visibility into the company's strategic priorities and growth initiatives.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.